Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université Laval

$25,000.00

Novel Glycoconjugate with PapMV Nanoparticules

EF 2015-16

Résumé
Development of synthetic carbohydrate-based vaccines (in which a cell surface polysaccharide is covalently attached to an appropriate carrier protein) is challenging and several problems have to be solved. For one thing, few adjuvants are currently authorized for human use; therefore, there is a major need for new adjuvants and immunomodulators related to carbohydrate-based vaccination. In that regards, there is a need for the development of a method to synthesize medically relevant polysaccharides as well as to test those as antigens using a novel potent vaccine platform to perform key experiments to improve our understanding of the biology and immunology of those crucial molecules. FOLIA BIOTECH INC showed that the papaya mosaic virus (PapMV) nanoparticles can activate innate immunity and be used as an adjuvant and/or a vaccine platform (to enhance the humoral immune response to peptides fused to its surface and presented to the immune system in an highly ordered manner). Additionally, FOLIA developed a technology that allow an efficient attachment of proteins to the PapMV nanoparticles. This strategy will be used to chemically attach glycans to the PapMV nanoparticles. To now, carbohydrate epitopes have never been tested with PapMV nanoparticles. The use of chemical synthesis to access those medically relevant carbohydrate residues is an interesting strategy. The proposed strategy will use a novel vaccine platform to increase immunogenicity of carbohydrate for generation of specific antibodies, which could ultimately lead to a carbohydrate-based antifungal vaccine. As a corollary, the proposed work will help validate the usefulness of new protein carriers related to carbohydrate research based on a novel vaccine platform. Furthermore, the proposed work would serve as a proof of concept on the utilization of the PapMV platform for the production of specific high tighter antibodies against other clinically important oligosaccharides, some of which elicit poor antibody responses.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
488746-2015
Name nom
Giguère, Denis
Department département
Chimie
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Novel Glycoconjugate with PapMV Nanoparticules
Keyword
NSERC
Application summary
Development of synthetic carbohydrate-based vaccines (in which a cell surface polysaccharide is covalently attached to an appropriate carrier protein) is challenging and several problems have to be solved. For one thing, few adjuvants are currently authorized for human use; therefore, there is a major need for new adjuvants and immunomodulators related to carbohydrate-based vaccination. In that regards, there is a need for the development of a method to synthesize medically relevant polysaccharides as well as to test those as antigens using a novel potent vaccine platform to perform key experiments to improve our understanding of the biology and immunology of those crucial molecules. FOLIA BIOTECH INC showed that the papaya mosaic virus (PapMV) nanoparticles can activate innate immunity and be used as an adjuvant and/or a vaccine platform (to enhance the humoral immune response to peptides fused to its surface and presented to the immune system in an highly ordered manner). Additionally, FOLIA developed a technology that allow an efficient attachment of proteins to the PapMV nanoparticles. This strategy will be used to chemically attach glycans to the PapMV nanoparticles. To now, carbohydrate epitopes have never been tested with PapMV nanoparticles. The use of chemical synthesis to access those medically relevant carbohydrate residues is an interesting strategy. The proposed strategy will use a novel vaccine platform to increase immunogenicity of carbohydrate for generation of specific antibodies, which could ultimately lead to a carbohydrate-based antifungal vaccine. As a corollary, the proposed work will help validate the usefulness of new protein carriers related to carbohydrate research based on a novel vaccine platform. Furthermore, the proposed work would serve as a proof of concept on the utilization of the PapMV platform for the production of specific high tighter antibodies against other clinically important oligosaccharides, some of which elicit poor antibody responses.